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that systolic dysfunction is common in DHF. Methods: Echocardiography with tissue Dop- 
pler imaging was performed in 339 subjects, in whom 92 had systolic heart failure (SHF) 
(ejection fraction <50%), 73 had DHF (ejection fraction =>50% with diastolic abnormali- 
ties on Doppler echocardiography), 68 had isolated diastolic dysfunction (DD) and 106 
normal controls. Regional myocardial velocity curves were constructed offline using a 6- 
basal, 6-mid segmental model. Results: The peak regional myocardial sustained systolic 
(Sm) and eady diastolic (Era) velocities were significantly lower in patients with SHF, 
DHF and DD than controls in almost all the myocardial segments. Likewise, the mean 
Sm (SHF < DHF < DD < Controls: 3.3 ± 1.0 < 4.6 ± 1.3 < 5.4 ± 1.0 < 6.3 ± 1.0 cm/s; all p 
<= 0.00t) and mean Em (SHF = DHF < DD < Controls; 3.6 ± 1.2 = 3.9 ± 1.3 < 5.3 ± 1.6 < 
7.2 ± 1.7 cm/s; all p < 0.001) from the six basal segments were decreased in all the dis- 
ease groups. A mean Sm of 4.4 em/s (-2 standard deviation of controls) predicted the 
presence of systolic dysfunction in 92% of patients with SHF, 52% with DHF and 14% 
with DD. Conclusions: Using tissue Doppler imaging, systolic abnormalities were evident 
in patients previously labeled as DHF, and to a much lesser extent, isolated DD. This 
indicates the common coexistence of systolic and diastolic dysfunction in a spectrum of 
different severity in the pathophysiologic process of heart failure. 
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Background. Prevalence of isolated LV diastolic dysfunction (IDD) has been reported to 
be as high as 1/3 of all chronic congestive heart failure (CHF) cases, with an increasing 
prevalence in the elderly population. However, there is a paucity of prospective data 
about the prevalence and prognosis of IDD in an unselected population of pts admitted to 
hospital with CHF. 
Methods. We prospectively evaluated 179 consecutive Lots admitted in medical depart- 
ments of our hospital for CHF. Among them, 135 (59% males, median age 74 years) 
showed sinus rhythm, and no significant valvulopathy (except heart valve prosthesis or 
secondary mitral regurgitation). CHF was diagnosed using a modification of the Framing- 
ham criteria, and IDD according to the European Study Group on Diastolic Heart Failure 
echo criteria (Eur Heart J 1998;19: 990). Six-month survival of CHF pts was compared 
with that of age- and sex-matched general population living in Udine in 1995. 
Results. Twenty-nine pts (22%) had tDD; 102 (76%) LV systolic dysfunction (i.e. LV ejec- 
tion fraction <45%. There was no difference in age, gender and NYHA functional class 
between pts with IDD or LV systolic dysfunction. Six-month rehospitalisation rate (50% 
and 48%) and median in-hospital length-of-stay during readmissions (10 and 10 days) 
was similar between the 2 groups. Using the Minnesota Living with Head Failure score, 
quality of life was similar between the 2 CHF pt groups both at discharge (39.4 and 34), 
and at 6-month visit (10.4 and 10.4). Six-month survival, adjusted for age and gender, 
was similar between pts with IDD or LV systolic dysfunction (90% and 89.8%, Hazard 
Ratio= 0.99; 95%CI 0.27-3.61), and significantly reduced (Log Rank= 8.58; p<0.001) in 
comparison to that of the general population (Figure). Two pts (7% of pts with LV ejection 
fraction< 45%) did not show any echo evidence of cardiac dysfunction. 
Conclusions: our data show that, using standardized echo diagnostic criteria, prevalence 
of IDD in pts admitted to hospital with CHF seems to be lower than previously reperted. 
CHF pts with IDD showed clinical symptoms, self-perceived quality of life, re-hospitaliza- 
tion rate, and 6-month mortality similar to pts with prevalent systolic dysfunction. 
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Background: Heart failure (CHF) is common cause of morbidity and mortality but cur- 
rent prevalence and long-term outcome are largely unknown in general population as 
opposed to pts setocted for clinical trials. 
Patients and Methods: 362 consecutive pts discharged from hospital with clinical CHF 
or suspected CHF (drug treatment compatible with CHF/LV dysfunction) were enrolled in 
CHF registry by prospective screening of internal medical, cardiac, intensive care and 
cardiac surgical departments in 2 hospitals (1 tertiary center with cardiac surgery, 1 refer- 
ral hospital) over 6 week period in each. Survival status at 1 yr was ascertained by tele- 
phone and from governmental records. 
Results: A quarter (90/362, 25%) of CHF pts died within 12 mths, a death rate higher 
than that reported in most recent clinical CHF trials. Pts who died were older (77±10 vs 
75±11 yrs, p=0.03), but death was not predicted by new acute myocardial infarction (AMI) 
or new atrial fibrillation (AF)/paroxysmal AF at time of entry to registry or by presence of 
diabetes mellitus (31/90, 34% vs 74/272, 27%, NS), nor following correction for age and 
sex in stepwise multivariate model. 
Conclusions: In pts hospitalized for CHF or suspected CHF in the real world: 1. Late (12 
mth) mortality was higher than expected. 2. Mortality was higher in older pts. 3. Death 
was not predicted by acute event at entry to database and was marginally but not signifi- 
cantly higher in diabetics. 
Predictors of 1 year mortality 
Vital status (12 Age (yrs) AMIonindex New AF/PAF on IDDM NIDDM 
mths) admission index admission 
Dead (N=90) 77+10 6 (7%) 7 (8%) 7 (8%) 24 (27%) 
Alive (N=272) 75+11 21 (8%) 24 (9%) 21 (6%) 53 (20%) 
p value 0,03 NS NS NS NS 
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1157-157 Impaired Left Ventricular Filltng Predicts Augmented 
Ventilatory Response to Exercise in Patients With 
Chronic Heart Failure 
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Sefan Anker, Massimo Pieopoli, Piotr Ponikowski, heart and lung institute, London, 
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Introduction. Augmented ventilator'/response to exercise ( VFJVCO 2 slope) well pre- 
dicts poor prognosis in chronic heart failure (CHF). However, the mechanisms responsi- 
ble for exercise hyperpnea in CHF have not been fully elucidated. The aim of this study 
was to determine the interrelationship between resting ECHO 2D-derived parameters 
and elevated VENCO 2 slope in CHF. Methods and results. In 38 stable CHF patients 
(33 men, 63±8 years, NYHA class fi/lll 26/12) prospective ECHO-2D examination (mean 
end diastolic diameter [EDD]: 68±8 mm, shortening fraction [SF]: 16±7%) followed by 
cardiopulmonary exercise testing (peak oxygen consumption: [peakVO2]: 19.0±6.3 ml/ 
min/kg, VENCO 2 slope 37.6±12.7). VENCO 2 slope correlated with the following 
echocardiographic parameters: short isovolumic relaxation time (IVRT, r=-0.47, 
p=0.005), decreased mitral A wave peak velocity (Ave I, r=-0.44, p=0.006), depressed 
right ventricle long axis function (RV excursion, r=-0.37, p=0.03), and left ventdcular 
restrictive filling pattern (defined as mitral E/A ratio > 1 and deceleration time ~120ms, 
r=0.47, p=0.004). There was no relationship between resting ECHO-2D indices and peak 
VO¢. Twenty (53%) pts with high VENCO 2 i.e. > 34.0) were identified: (table). 
EDD (mm) SF(%) Ave I (m/s) IVRT (ms) RV excursion Restrictive 
(ram) mitral flow 
(%) 
High VENCO 2 68±8 17±7 0.4±0.3** 24±59 12±4" 65* 
(n=20) 
Normal VE/VCO 2 68±8 18±7 0.8±0.3 50±25 17±4 29 
(n=18) 
Mean ± SD, *p<0.05, **p<0.01 high vs normal VE/VCO2Conclueion: In CHF impaired 
left ventricular filling pattern and depressed right ventricle long axis function may be 
important factors responsible for augmented ventilatory response to exercise. 
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Background: The benefits of beta blockers (BB) in patients with chronic heart failure 
(CHF) are well established, however, there is limited data on the impact of BB in diabetic 
CH F patients, a subgroup in whom BB have been considered relatively ocntra-indicatad. 
The aim of this study was to compare the efficacy and tolerability of the BB, carvedilol in 
diabetic and non-diabetic CHF patients. 
Methods: A retrospective analysis was conducted on 505 consecutive patients with CHF 
(434 men, 71 women) aged 55+13 years who were commenced on carvedilol between 
February 1996 and May 2001. Ninety-three patients (18%) had a history of diabetes mel- 
litus (DM group). Patients were reviewed at 3, 6, 12, 18 and 24 months then annually. 
Vital signs, NYHA functional class, 6 minute walk distance (6MWD), carvedilol dose and 
echocardiographic measurements of LV dimensions (LVEDD and LVESD) and fractional 
shortening (FS) were recorded at each visit. In addition, survival and non-fatal adverse 
events were recorded. 
Results: There were no significant differences between the DM and non-DM groups at 
baseline with respect to age, sex, duration of CHF, heart rate, diastolic blood pressure, 
serum Na+ and creatinine, drug therapy, NYHA class, LV dimensions and function. The 
DM group were significantly heavier, had lower 6MWD, and higher systolic blood pres- 
sure at baseline. A higher percentage of diabetics had ischemic heart disease (54% v 
37%, p=0.007). During a mean follow up of 32+18 months, 22% of the DM group died, 
12% underwent heart transplantation (HTx) and 11% withdraw from carvedilol due to 
adverse events. In comparison, 19% of the non-DM group died, 9% underwent HTx and 
18% were withdrawn from carvedilot due to adverse events (all p=ns compared with DM 
group). Mean maintenance carvedilol doses were 42+2 and 39+3 rag/day for DM and 
non-DM groups (p=ns). At 24 months, NYHA class and 6MWD improved significantly, 
LVEDD fell by 3.1±0.5 mm, LVESD by 4.9±0.6 mm and FS rose by 3±1% (all p < 0.0001 
versus baseline, n=226), with no significant differences between the DM and non-DM 
groups. 
Conclusion: The tolerability, clinical outcomes and beneficial effects of carvedilol on LV 
remodelling are similar in diabetic and non-diabetic CHF patients. 
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Henrv Krum. Paul Mohacsi, Hugo A. Katus, Michal Tendera, Jean L. Rouleau, Michael B. 
Fowler, Andrew J. Coats, Ellen B. Roecker, Milton Packer, for the COPERNICUS Study 
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Background. The results of the VaI.HeFT study suggested that broad based neurohor- 
monal blockade may have deleterious effects in patients with heart failure (HF), but this 
hypothesis has not been evaluated in other trials. 
Methods. The 2289 patients with severe HF in the COPERNICUS trial were randomized 
to placebo (PBO) or carvedilol (CRV), which were added to diuretics and an ACE inhibi- 
tor (+ digitalis) for up to 29 months. Of these patients, 445 were also on spironolactone at 
baseline and thus received 3 neurohormonal antagonists if they were randomized to 
CRV. Compared with those not on spironolactone, patients on spironolactone had a 
